Cyfuse Biomedical K.K.

¥500.00As of Sun 8 Nov 2026, 12:00 UTC
TSE:4892Healthcare
Country Japan
PE (Fwd) •••
TSR 4Y CAGR (21.97%)
Div yield —
ROE (32.11%)
Biotechnology
Beta (5Y) 1.30
PE TTM —
TSR TTM (12.74%)
Mkt cap ¥4.982B
ROIC (169.96%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥485
(2.93%)
(84.57%)
Hold 4|2|11|1|6
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
7.75
8.23
9.07
9.93
30.27%
29.09%
33.45%
42.92%
Revenue¥M
266.8
266.2
261.8
258.8
8.67%
2.72%
2.27%
(3.05%)
Peers (US$31.63M)
Cap (US$)
PE
32.55M
24.18x
29.46M
—
Capital
TTM
5Y
10Y
Leveragex
3.557
0.124
0.112
EBIT/Intx
7.410
1.049
0.911
Own earn%
73.10
(144.53)
(118.52)
Sh yield%
10.70
20.31
20.87
Owners
Insiders/Inst%
13.54
56.19
Short interest%
1.90
SBC / revenue%
3.94
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
9–13
$1 testx
0.0
Incr. ROIC%
9